Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R N Brogden

Showing results (31-40 of 251) with videos related to

Pageof 26
Sort By:
Drugs|October 1, 1988
Xamoterol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic useR Furlong, R N Brogden
Drugs|March 1, 1985
Tiaprofenic acid. A review of its pharmacological properties and therapeutic efficacy in rheumatic diseases and pain statesE M Sorkin, R N Brogden
Drugs|November 1, 1987
Nedocromil sodium. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of reversible obstructive airways diseaseJ P Gonzalez, R N Brogden
Drugs|August 1, 1985
Pirenzepine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseasesA A Carmine, R N Brogden
Drugs|March 20, 1998
Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthmaR A Bartow, R N Brogden
Drugs|October 1, 1986
Oxaprozin. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacyP A Todd, R N Brogden
Drugs|February 1, 1996
Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disordersC M Perry, R N Brogden
Drugs & Aging|November 1, 1996
Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasiaG L Plosker, R N Brogden
Drugs|October 1, 1994
Dirithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacyR N Brogden, D H Peters
Drugs|April 1, 1995
Isradipine. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertensionR N Brogden, E M Sorkin
Pageof 26

Showing results (31-40 of 251) with videos related to

Sort By:
Pageof 26
Drugs|October 1, 1988
Xamoterol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic useR Furlong, R N Brogden
Drugs|March 1, 1985
Tiaprofenic acid. A review of its pharmacological properties and therapeutic efficacy in rheumatic diseases and pain statesE M Sorkin, R N Brogden
Drugs|November 1, 1987
Nedocromil sodium. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of reversible obstructive airways diseaseJ P Gonzalez, R N Brogden
Drugs|August 1, 1985
Pirenzepine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseasesA A Carmine, R N Brogden
Drugs|March 20, 1998
Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthmaR A Bartow, R N Brogden
Drugs|October 1, 1986
Oxaprozin. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacyP A Todd, R N Brogden
Drugs|February 1, 1996
Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disordersC M Perry, R N Brogden
Drugs & Aging|November 1, 1996
Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasiaG L Plosker, R N Brogden
Drugs|October 1, 1994
Dirithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacyR N Brogden, D H Peters
Drugs|April 1, 1995
Isradipine. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertensionR N Brogden, E M Sorkin
Pageof 26